A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ...
The struggling cell therapy developer is exploring strategic alternatives, which, among other characteristics, make it a ...
The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results